This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
OKYO Overzicht aandelen
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 2 meer risico's
OKYO Pharma Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | UK£0.91 |
| 52 Week Hoogtepunt | UK£3.90 |
| 52 Week Laag | UK£0.88 |
| Bèta | -0.062 |
| 11 maand verandering | -9.68% |
| 3 maanden verandering | -65.69% |
| 1 Jaar Verandering | -63.64% |
| 33 jaar verandering | -45.10% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -98.13% |
Recent nieuws en updates
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02Rendement voor aandeelhouders
| OKYO | GB Biotechs | GB Markt | |
|---|---|---|---|
| 7D | -31.7% | 1.2% | 1.2% |
| 1Y | -63.6% | -13.6% | 11.6% |
Rendement versus industrie: OKYO underperformed the UK Biotechs industry which returned -16.5% over the past year.
Rendement versus markt: OKYO underperformed the UK Market which returned -2.2% over the past year.
Prijsvolatiliteit
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stabiele aandelenkoers: OKYO's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: OKYO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited Samenvatting
| OKYO fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | UK£23.22m |
| Inkomsten(TTM) | -UK£6.70m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-3.5x
Koers/WinstverhoudingIs OKYO overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| OKYO resultatenrekening (TTM) | |
|---|---|
| Inkomsten | UK£0 |
| Kosten van inkomsten | UK£4.39m |
| Brutowinst | -UK£4.39m |
| Overige uitgaven | UK£2.31m |
| Inkomsten | -UK£6.70m |
Laatst gerapporteerde inkomsten
Sep 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.26 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde OKYO op de lange termijn?
Bekijk historische prestaties en vergelijking